Seaport Research raised the firm’s price target on Hims & Hers to $28 from $26 and keeps a Buy rating on the shares. The company reported “strong” Q2 results, with upside to revenue driven by adoption of personalized solutions, the analyst tells investors. While there is some uncertainty around the durability of the company’s ability to sell compounded GLP-1s, the company is also seeing strong growth of its oral based solution and expects additional weight loss solutions to emerge that will broaden its offerings, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- HIMS Upcoming Earnings Report: What to Expect?
- Truist says FDA GLP-1 adverse events report ‘likely a non-event’ for Hims & Hers
- FDA warns of possible overdoses with compounded semaglutide injections
- Hims & Hers lower after FDA warns of dosing errors with Ozempic
- Hims and Hers Health call volume above normal and directionally bullish